Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Prevention Research
Cancer Prevention Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Letter to the Editor

Mutations of the PDE5A Gene Confer a Survival Advantage in Patients with Colon Cancer

Steven Lehrer, Peter H. Rheinstein and Kenneth E. Rosenzweig
Steven Lehrer
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: steven.lehrer@mssm.edu
Peter H. Rheinstein
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth E. Rosenzweig
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1940-6207.CAPR-18-0105 Published July 2018
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Islam and colleagues report that sildenafil suppresses inflammation-driven colorectal cancer in mice (1). Intestinal cyclic guanosine monophosphate (cGMP) signaling regulates epithelial homeostasis and has been implicated in the suppression of colitis and colon cancer. In their study, Islam and colleagues demonstrated that the cGMP-elevating ability of the phosphodiesterase-5 (PDE5) inhibitor sildenafil can prevent cancer in the azoxymethane/dextran sulfate sodium inflammation-driven colorectal cancer mouse model.

Here, we use data from The Cancer Genome Atlas (TCGA) to assess survival of colon cancer patients with and without mutations of the PDE5A gene.

We assessed the association between PDE5A and colon cancer overall survival using the GDC TCGA Colon Cancer (COAD) cohort in TCGA database. To access and analyze the data, we used the UCSC Xena browser (https://xenabrowser.net). Survival data of the mutant and unmutated PDE5A subgroups were extracted for analysis and generation of Kaplan–Meier curves for overall survival.

Data from 371 patients were analyzed. The tumors were all primary, and each patient had only one tumor. The mean age at diagnosis was 67.1 ± 13.1 (mean ± SD). A total of 51.9% were male, 48.1% were female. 52.4% were white, 14.2% were African American, 2.5% were Asian, and 30.6% were unreported.

A total of 359 patients had an unmutated PDE5A gene. Twelve patients had a mutant PDE5A gene. The PDE5A gene had one or more of these mutations:

  • Frameshift variant

  • Stop gained

  • Splice acceptor variant

  • Missense variant

  • Synonymous variant

  • Splice region variant

Ten of the 12 mutant PDE5A genes had a single mutation. One of the mutant genes had two mutations (stop gained + missense); the other had three mutations (stop gained + 2 missense).

Survival of colon cancer patients is shown in Fig. 1. A total of 359 patients with no mutation of PDE5A had significantly poorer survival than 12 patients with mutation of PDE5A. The effect of the mutation is significant (log-rank 3.814, P = 0.05).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Survival of colon cancer patients, 359 with no mutation of PDE5A (lower curve), 12 with mutation of PDE5A (upper line). The effect of the mutation is significant (log-rank 3.814, P = 0.05).

Chronic inflammation is involved in many forms of cancer. Aspirin and other NSAIDs reduce the risk of multiple cancer types due to their anti-inflammatory properties. Another NSAID, sulindac, inhibits the development of cancer through PDE5 suppression.

Sildenafil is a small molecule that inhibits PDE5. The study of Islam and colleagues validates PDE5 as a colon cancer chemoprevention target in mice (2), as did a second mouse study (3). Our analysis of TCGA data corroborates this finding in humans. Further studies are needed to determine whether sildenafil or other PDE5 inhibitors might be colon cancer preventives or treatments.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

  • Received March 25, 2018.
  • Revision received April 16, 2018.
  • Accepted April 25, 2018.
  • Published first May 3, 2018.
  • ©2018 American Association for Cancer Research.

References

  1. 1.↵
    1. Islam BN,
    2. Sharman SK,
    3. Hou Y,
    4. Bridges AE,
    5. Singh N,
    6. Kim S,
    7. et al.
    Sildenafil suppresses inflammation-driven colorectal cancer in mice. Cancer Prev Res 2017;10:377–88.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Piazza GA
    . Validation of PDE5 as a Chemoprevention Target. Cancer Prev Res 2017;10:373.
    OpenUrlFREE Full Text
  3. 3.↵
    1. Lin S,
    2. Wang J,
    3. Wang L,
    4. Wen J,
    5. Guo Y,
    6. Qiao W,
    7. et al.
    Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC. Am J Cancer Res 2017;7:41–52.
    OpenUrlPubMed
PreviousNext
Back to top
Cancer Prevention Research: 11 (7)
July 2018
Volume 11, Issue 7
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Prevention Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Mutations of the PDE5A Gene Confer a Survival Advantage in Patients with Colon Cancer
(Your Name) has forwarded a page to you from Cancer Prevention Research
(Your Name) thought you would be interested in this article in Cancer Prevention Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Mutations of the PDE5A Gene Confer a Survival Advantage in Patients with Colon Cancer
Steven Lehrer, Peter H. Rheinstein and Kenneth E. Rosenzweig
Cancer Prev Res July 1 2018 (11) (7) 439-440; DOI: 10.1158/1940-6207.CAPR-18-0105

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Mutations of the PDE5A Gene Confer a Survival Advantage in Patients with Colon Cancer
Steven Lehrer, Peter H. Rheinstein and Kenneth E. Rosenzweig
Cancer Prev Res July 1 2018 (11) (7) 439-440; DOI: 10.1158/1940-6207.CAPR-18-0105
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Disclosure of Potential Conflicts of Interest
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • HER2 Expression in NF1 Breast Cancer—Response
  • NF1 Alterations are Linked to Increased HER2 Expression in Breast Cancer–Letter
Show more Letter to the Editor
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Prevention Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Prevention Research
eISSN: 1940-6215
ISSN: 1940-6207

Advertisement